CLEVELAND & LEXINGTON, Ky. (BUSINESS WIRE) Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the.